Hence, sPD-1 represents an excellent candidate for exploitation as therapeutic strategy in cancer patients as single agent, to complement immunotherapy and other traditional cancer treatments, and as an adjuvant with gene therapies and vaccines. The gene discussed is HOXD13; the disease is cancer.